Sign in

Jason Norman

@jnorman.bsky.social
691 followers 415 following 12 posts

Microbe host, researcher, microbiome drug developer at Vedanta Biosciences

PostsRepliesMedia
Jason Norman @jnorman.bsky.social · 05/04/2025
looking forward to #ESCMIDGlobal next week in Vienna. I'd love to connect and discuss developing microbiome drugs to prevent infection. Come to the Innovation Theater 12 April at 11:30!
122
Reposted by Jason Norman
Darren Incorvaia @megadarren.bsky.social · 01/04/2025
If you're a scientist at the NIH or another HHS agency who was affected by today's RIF, I'd love to hear about the work you were doing and how important it was for our nation's health! I'm a staff writer at Fierce Biotech, and I can be reached through DM on BlueSky or securely on Signal at dinc.49
011858
Reposted by Jason Norman
Wiep Klaas Smits (ExpBac/CMAT) @smitslab.bsky.social · 30/01/2025
New publication: This is work stems from the mind of Quinten Ducarmon, and was led by PhD student Sam Nooij. Our group contributed to the culturing of the isolates and generating the complete genomes. What 's in this manuscript? 👇 www.nature.com/articles/s41...
nature.com
Metagenomic global survey and in-depth genomic analyses of Ruminococcus gnavus reveal differences across host lifestyle and health status - Nature Communications
Here, the authors present a global meta-analysis of the human gut bacterium Ruminococcus gnavus, established an isolate collection with complete genomes and identified genetic features correlating wit...
293
Reposted by Jason Norman
Bernat Olle @bernatolle.bsky.social · 24/01/2025
www.businesswire.com/news/home/20...
businesswire.com
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today annou
041
Jason Norman @jnorman.bsky.social · 04/01/2025
Our team published additional results from the Phase 2 CONSORTIUM study for our rCDI candidate, VE303. This research offers new insights into PK-PD relationships and the mechanisms of action of VE303, providing a rationale for the drug’s protective effects in rCDI. www.nature.com/articles/s41...
nature.com
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection - Nature Medicine
Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a phase 2 trial show rob...
062
Jason Norman @jnorman.bsky.social · 03/12/2024
Reposting from the other place.. I am looking to hire a Bioinformatics Scientist to join the Systems Biology team at Vedanta Biosciences, Inc. We're considering candidates local to Boston and up to 100% remote (if in the US). Please help me spread the word job-boards.greenhouse.io/vedantabiosc...
job-boards.greenhouse.io
Job Application for Scientist I/II, Bioinformatics at Vedanta Biosciences
012
Reposted by Jason Norman
Scott Saunders @saunderslab.bsky.social · 22/11/2024
Wow - bluesky! 📈 🦠 Please help me amplify a special faculty search. We're looking for someone in "Microbial Systems Biology" to join me and @kreynoldslab.bsky.social at UTSW Sys Bio / Bioinformatics. There is an empty lab space right next to us waiting for you! apply.interfolio.com/154339 1/4
chalk + chalkboard with diagramslab group silly picture
394103
Reposted by Jason Norman
Justin Silverman @inschool4life.bsky.social · 22/11/2024
Nice paper by Nishijima et al, from Bork's lab using machine learning to show that the absolute bacterial load is a major confounder in most human microbiome studies (www.cell.com/cell/fulltex.... Now seems a good time to outline the approaches that we have been developing.
cell.com
162
Jason Norman @jnorman.bsky.social · 21/11/2024
Hello world. I'm a researcher at Vedanta Biosciences where we are developing defined bacterial consortia to modulate the microbiome and treat or prevent human disease. General focus areas: microbial ecology, drug discovery, IBD and infectious disease. Wordcloud via scholargoggler.com
093
Reposted by Jason Norman
Stephen Turner @stephenturner.us · 20/11/2024
Another lovely feature of this platform to decelerate the dunking/hot takes: if someone has quote-posted you with negative/snarky commentary, you can detach your post from their quote. You can also turn quote posts off altogether when composing a new post.
0154
Jason Norman @jnorman.bsky.social · 19/11/2024
A great opportunity for sure 👇🏻
010
Reposted by Jason Norman
Stephen Turner @stephenturner.us · 15/11/2024
A thread with some new starter packs in genomics and bioinformatics 🧵 1/13...
812455
Jason Norman @jnorman.bsky.social · 13/11/2024
shout out to BioRender users... NIAID created a free version bioart.niaid.nih.gov
bioart.niaid.nih.gov
Bioart
010
Jason Norman @jnorman.bsky.social · 13/11/2024
I'm looking to grow my #microbiome research network in the platform. Is there a way to search for starter packs? Any recommendations?
120
Jason Norman @jnorman.bsky.social · 13/11/2024
Feeling inspired by the @bsky.app growth. Might just have to get back into the social media groove. Keep posting all things science and drug dev y’all.
010
Jason Norman @jnorman.bsky.social · 17/05/2024
really looking forward to #DDW2024 and to share some of the latest research from VedantaBio on the VE303 defined consortium for preventing rCDI. I'd love to connect.
020